In addition, studies have confirmed the inhibitory effect of SGLT2 inhibitors such as Canagliflozin on CDK1 and the subsequent cell cycle arrest at the G2/M in hepatocellular carcinoma [67]. The gene discussed is SLC5A2; the disease is hepatocellular carcinoma.